Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Robert Bissonnette
Rethinking Low Disease Activity in Atopic Dermatitis—Reply
In Reply We thank Bunick for his thoughtful commentary on the International Eczema Council (IEC) definitions of low disease activity (LDA), very low disease activity (vLDA), and remission in atopic dermatitis (AD).1 We agree that the patient experience is essential to the continued evaluation and refinement of these concepts and trial-facing definitions must be contextualized within the broader framework of clinical practice.
Icotrokinra induces early and sustained pharmacodynamic responses in phase IIb study of patients with moderate-to-severe psoriasis
Abstract Introduction Psoriasis is a common, chronic, immune-mediated, inflammatory disease affecting around 2%–4% of the population in Western countries (1), with plaque psoriasis accounting for about 90% of cases (2). The pathogenesis of psoriasis involves a complex interplay between T cells, innate immune cells, and keratinocytes (3). Cytokines and other inflammatory mediators secreted by immune cells drive leukocyte infiltration and keratinocyte proliferation (3).
Ruxolitinib Cream Demonstrated Rapid Reductions in Itch and Atopic Dermatitis Signs That Correlated With Biomarkers
Keywords Janus kinase inhibitor serum biomarker skin barrier function skin biomarker SCRATCH-AD Abbreviations AD (atopic dermatitis) BSA (body surface area) CCL (C-C motif chemokine ligand) DEFB (defensin beta) IGA (Investigator’s Global Assessment) IGA-TS (Investigator’s Global Assessment Treatment Success) IL (interleukin) ITT (intent to treat) JAK (Janus kinase) mITT (modified intent to treat) mPP-NRS (modified Peak Pruritus Numerical Rating Scale) PP-NRS (Peak Pruritus Numerical Rating...
Oral Icotrokinra for Plaque Psoriasis in Adults and Adolescents | NEJM
Notes A data sharing statement provided by the authors is available with the full text of this article at NEJM.org. Supported by Johnson & Johnson. Disclosure forms provided by the authors are available with the full text of this article at NEJM.org. We thank all the trial participants and their families, investigators, and trial coordinators. The first draft was written by Panita M.
Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials
Get full text access Log in, subscribe or purchase for full access. References 1. Griffiths, CEM ∙ Armstrong, AW ∙ Gudjonsson, JE ∙ et al. Psoriasis Lancet. 2021; 397:1301-1315 2. Elloso, MM ∙ Gomez-Angelats, M ∙ Fourie, AM Targeting the Th17 pathway in psoriasis J Leukoc Biol. 2012; 92:1187-1197 3.
The hf-PGA is a valid and reliable measure of hand/foot psoriasis severity in adults: results from a phase 2b clinical trial
Abstract The objective was to investigate the reliability, validity, and meaningful change scores for the Physician’s Global Assessment of Hands and/or Feet (hf-PGA), a measure of clinician-reported psoriasis severity on the hands/feet. Baseline, Week 8, and Week 16 data were analyzed from adult patients with moderate to severe plaque psoriasis (n = 99) in a Phase 2b multicenter, randomized, placebo-controlled, dose-ranging study (NCT05223868).
Expert Perspectives: Dermatology's Top Story to Watch in 2025
Published on: , , , , , , , , A group of 9 experts reflect on what they are looking forward to most in 2025 following the AAD annual meeting. Although nearly all medical professionals can point to a “flagship” meeting or annual conference for their specialty, few serve the same role as or measure up to what the American Academy of Dermatology annual meeting means for the field of dermatology.
Positive results showcase icotrokinra’s ‘unique’ mechanism of action in plaque psoriasis
These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.
Icotrokinra, Plaque Psoriasis, and ICONIC-LEAD, with Robert Bissonnette, MD
New data from the ICONIC-LEAD trial suggest icotrokinra could soon a major role in dermatology’s armamentarium for the management of plaque psoriasis. Presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting, results of the phase 3 study demonstrate the benefit of icotrokinra among adults with moderate to severe plaque psoriasis.
Mission impossible? Caveats in interpreting and comparing long‐term efficacy in biologic studies for moderate‐to‐severe plaque psoriasis
DATA AVAILABILITY STATEMENT The data that support the findings of this study are available from the corresponding author upon reasonable request.
Dupilumab in Adults With Moderate to Severe Atopic Dermatitis: A 5-Year Open-Label Extension Study
Ayuda Buscar en la ayuda Buscar en la ayuda Dupilumab in Adults With Moderate to Severe Atopic Dermatitis: A 5-Year Open-Label Extension Study Autores: Lisa A. Beck, Robert Bissonnette, Mette S. Deleuran, Takeshi Nakahara, Ryszard Galus, Anna Coleman, Guy Gherardi, Jing Xiao, Robert Dingman, Christine Xu, Elena Avetisova, Ariane Dubost Brama, Arsalan Shabbir Localización: JAMA Dermatology, ISSN 2168-6068, Vol. 160, Nº. 8, 2024, págs.
Treat-to-Target Outcomes With Tapinarof Cream 1% in Phase 3 Trials for Plaque Psoriasis
Psoriasis is a chronic inflammatory disease affecting approximately 8 million adults in the United States and 2% of the global population.1,2 Psoriasis causes pain, itching, and disfigurement and is associated with a physical, psychological, and economic burden that substantially affects health-related quality of life.3-5 Setting treatment goals and treating to target are evidence-based approaches that have been successfully applied to several chronic diseases to improve patient outcomes,...
Dupilumab in Adults With Moderate to Severe Atopic Dermatitis
Key Points Question What is the long-term safety and efficacy of dupilumab in adults with moderate to severe atopic dermatitis? Findings In this open-label extension study of 2677 adults with moderate to severe atopic dermatitis, dupilumab was well tolerated with no new safety incidents and showed sustained efficacy (including improvements in atopic dermatitis signs, symptoms, and quality of life) for up to 5 years.
An Oral Interleukin-23–Receptor Antagonist Peptide for Plaque Psoriasis | NEJM
February 8, 2024 N Engl J Med 2024; 390:510-521 DOI: 10.1056/NEJMoa2308713 Abstract The use of monoclonal antibodies has changed the treatment of several immune-mediated inflammatory diseases, including psoriasis. However, these large proteins must be administered by injection. JNJ-77242113 is a novel, orally administered interleukin-23–receptor antagonist peptide that selectively blocks interleukin-23 signaling and downstream cytokine production.
Clinical and molecular effects of oral CCR4 antagonist RPT193 in atopic dermatitis: A Phase 1 study
CCL17 C-C motif chemokine ligand 17 CCL22 C-C motif chemokine ligand 22 CCR4 C-C motif chemokine receptor 4 EASI Eczema Area and Severity Index EOT end of treatment MAD multiple ascending dose MADAD meta-analysis derived atopic dermatitis NL non-lesional SAD single ascending dose SCORAD SCORing Atopic Dermatitis Th T-helper cell 1 INTRODUCTION Atopic dermatitis (AD) is a chronic inflammatory skin disease that is estimated to affect ~15%–20% of children and up to 10% of adults worldwide, with...
Rapid and Early Onset of Itch Relief with Tapinarof Cream 1% Once Daily in Two Pivotal Phase 3 Trials in Adults and Children Down to Two Years of Age with Atopic Dermatitis | SKIN The Journal of Cutaneous Medicine
1. Silverberg JI, et al. Ann Allergy Asthma Immunol. 2018;121:340–347. 2. LeBovidge JS, et al. J Pediatr Psychol. 2007;32:617–625. 3. Meltzer LJ, et al. Ann Allergy Asthma Immunol. 2020;124:385–392. 4. Birdi G, et al. Int J Dermatol. 2020;59:e75–e91. 5. Dermavant Sciences. VTAMA (tapinarof) cream, 1%: US prescribing information. 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215272s000lbl.pdf. Accessed September 2023. 6. Kircik L, et al.
The vIGA‐AD scale for atopic dermatitis: Uptake in the past 5 years and position of the International Eczema Council
Please review our Terms and Conditions of Use and check box below to share full-text version of article. I have read and accept the Wiley Online Library Terms and Conditions of Use Use the link below to share a full-text version of this article with your friends and colleagues. Learn more.
Ethnicity, Race and Skin Color: Challenges and Opportunities for Atopic Dermatitis Clinical Trials
Open AccessReview by *, , and Innovaderm Research Inc., 3530 St-Laurent St, Suite 300, Montreal, QC H2X 2V1, Canada * Author to whom correspondence should be addressed. J. Clin. Med.
Treat-to-Target Outcomes and Measures of Treatment Success in Three Phase 3 Trials of Tapinarof Cream 1% Once Daily for Mild to Severe Plaque Psoriasis | SKIN The Journal of Cutaneous Medicine
1. Armstrong AW, et al. J Am Acad Dermatol. 2017;76:290–298. 2. Pathirana D, et al. J Eur Acad Dermatol Venereol. 2009;23:5–70. 3. Mahil SK, et al. Br J Dermatol. 2020;182:1158–1166. 4. Strober BE, et al. Dermatol Ther. 2019;9:5–18. 5. Bagel J and Stein Gold L. J Drugs Dermatol. 2017;16:1209–1222. 6. Armstrong A, et al. J Eur Acad Dermatol Venereol. 2018;32:2200–2207. 7. Elmets CA, et al. J Am Acad Dermatol. 2021;84:432-470. 8. Dermavant Sciences. VTAMA (tapinarof) cream, 1%: US prescribing information. 2022.
Dupilumab inhibits vascular leakage of blood proteins into atopic dermatitis skin
Atopic dermatitis (AD) skin lesions are associated with oozing, bleeding, and erythema that are primarily driven by polarized type 2 immune responses. These suggest vascular changes in AD. Dupilumab is an antibody to the alpha-subunit of interleukin (IL)-4 receptor that demonstrates robust efficacy in the treatment of moderate-to-severe AD. IL-4 is known to reduce the permeability barrier function of vascular endothelium. The effect of dupilumab on vascular barrier function in AD is unknown.
Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study
Summary Background Prurigo nodularis is a chronic skin disease characterised by intensely pruritic, hyperkeratotic nodules. Vixarelimab, a human monoclonal antibody, binds to the beta subunit of the oncostatin M receptor, inhibiting signalling of both interleukin 31 and oncostatin M, two cytokine pathways that contribute to pruritus and nodule formation in prurigo nodularis.
Dermavant to Present Data from Multiple Studies of VTAMA® (tapinarof) cream, 1% at the 2023 Winter Clinical Dermatology Conference
LONG BEACH, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Jan 12, 2023-- Dermavant Sciences, a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced that data from multiple studies of VTAMA ® (tapinarof) cream, 1%, will be presented at the 20 th Annual Winter Clinical Dermatology Conference, to be held January 13 to 18 in Hawaii.
Dermavant to Present Data from Multiple Studies of VTAMA┬" (tapinarof) cream, 1% at the 2023 Winter Clinical Dermatology Conference
LONG BEACH, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Jan 12, 2023-- Dermavant Sciences, a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced that data from multiple studies of VTAMA ® (tapinarof) cream, 1%, will be presented at the 20 th Annual Winter Clinical Dermatology Conference, to be held January 13 to 18 in Hawaii.
Treat-to-Target Outcomes and Measures of Treatment Success in Three Phase 3 Trials of Tapinarof Cream 1% Once Daily for Mild to Severe Plaque Psoriasis | SKIN The Journal of Cutaneous Medicine
1. Armstrong AW, et al. J Am Acad Dermatol. 2017;76:290–298. 2. Pathirana D, et al. J Eur Acad Dermatol Venereol. 2009;23:5–70. 3. Mahil SK, et al. Br J Dermatol. 2020;182:1158–1166. 4. Strober BE, et al. Dermatol Ther. 2019;9:5–18. 5. Bagel J and Stein Gold L. J Drugs Dermatol. 2017;16:1209–1222. 6. Armstrong A, et al. J Eur Acad Dermatol Venereol. 2018;32:2200–2207. 7. Elmets CA, et al. J Am Acad Dermatol. 2021;84:432-470. 8. Dermavant Sciences. VTAMA (tapinarof) cream, 1%: US prescribing information. 2022.
A Phase 2 Study of Oral Difelikefalin for Moderate-to-Severe Pruritus in Subjects With Notalgia Paresthetica (KOMFORT)
Main Article Content Keywords notalgia paresthetica, KOMFORT, difelikefalin, phase 2, clinical trial References 1. Ellis C. Dermatol Pract Concept. 2013;3:3-6 2. Fishbane S, et al. N Engl J Med. 2020;382:222-232 3. Topf J, et al. Kidney Med. 2022;4(8):100512 4. Korsuva. Package insert. Cara Therapeutics, Inc.; 2021 5. Kapruvia. Summary of product characteristics. Vifor Fresenius Medical Care Renal Pharma France; 2022 6. Kim BS, et al. Oral difelikefalin reduces pruritus in atopic dermatitis.
Dermavant to Present Data from Multiple Clinical Trials of VTAMA® (tapinarof) cream, 1% at the 2022 Fall Clinical Dermatology Conference
LONG BEACH, Calif., and BASEL, Switzerland--(BUSINESS WIRE)--Oct 13, 2022-- Dermavant Sciences, a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced it will present data from multiple studies of VTAMA ® (tapinarof) cream, 1% at the 2022 Fall Clinical Dermatology Conference from October 20-23 in Las Vegas.
Dermavant to Present Data from Multiple Clinical Trials of VTAMA® (tapinarof) cream, 1% at the 2022 Fall Clinical Dermatology Conference
LONG BEACH, Calif., and BASEL, Switzerland--(BUSINESS WIRE)-- Dermavant Sciences Inc., a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced it will present data from multiple studies of VTAMA®(tapinarof) cream, 1% at the 2022 Fall Clinical Dermatology Conference from October 20-23 in Las Vegas.
Dermavant to Present Data from Multiple Clinical Trials of VTAMA® (tapinarof) cream, 1% at the 2022 Fall Clinical Dermatology Conference
LONG BEACH, Calif., and BASEL, Switzerland--(BUSINESS WIRE)--Oct 13, 2022-- Dermavant Sciences, a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced it will present data from multiple studies of VTAMA ® (tapinarof) cream, 1% at the 2022 Fall Clinical Dermatology Conference from October 20-23 in Las Vegas.
One-year safety and efficacy of tapinarof cream for the treatment of plaque psoriasis: Results from the PSOARING 3 trial
Background Tapinarof cream 1% once daily, an aryl hydrocarbon receptor-modulating agent, was significantly more efficacious than vehicle and well tolerated in two 12-week phase 3 trials in adults with mild to severe plaque psoriasis. Objective To assess long-term safety, efficacy, remittive effect, durability of response, and tolerability of tapinarof. Methods Patients completing the 12-week trials were eligible for 40-weeks’ open-label treatment and 4-weeks’ follow-up.
The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA‐AD™): a clinical outcome measure for the severity of atopic dermatitis
Analytical methods The psychometric evaluation within the BREEZE-AD1, -AD2 and -AD5 studies employed blinded data. All analyses were conducted on the full intent-to-treat population, or the relevant intent-to-treat-derived population as specified in each analysis. The performance of the vIGA-AD was evaluated with respect to prespecified thresholds for acceptability. The vIGA-AD was completed at every study visit associated with clinician-rated outcomes (ClinROs).
Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Long-Term Extension Trial of a Novel Therapeutic Aryl Hydrocarbon Receptor Modulating Agent
Main Article Content Bruce Strober Yale University, New Haven & Central Connecticut Dermatology Research, Cromwell, CT, USA, Linda Stein Gold Henry Ford Health System, Detroit, MI, USA Robert Bissonnette Innovaderm Research, Montreal, QC, Canada April Armstrong University of Southern California Andrew Blauvelt Oregon Medical Research Center, Portland, OR, USA Leon Kircik Skin Sciences PLLC Philip Brown Dermavant Sciences, Inc., Morrisville, NC, USA Anna Tallman Dermavant Sciences, Inc.,...
Dupilumab treatment significantly improves skin barrier function in adult and adolescent patients with moderate to severe atopic dermatitis
Safety of Long-Term Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis up to 172 Weeks: Results from an Open-Label Extension (OLE) Trial
Montreal Dermatology Research Institute Launches New Website and Grant Program
Funding opportunity helps advance research into skin-related neglected tropical diseases This program has the potential to not only drive clinical research, but to also pave the way to new interventions that can have a significant impact on the quality of life of individuals.” — Dr. Robert Bissonnette MONTREAL, QUEBEC, CANADA, December 15, 2021 / EINPresswire.com/ -- The Montreal Dermatology Research Institute (MDRI) will soon be unveiling its new website and introducing a multi-year grant...
L'Institut de recherche en dermatologie de Montréal lance un nouveau site web et un programme de subventions
L'opportunité de financement permet d'accélérer la recherche sur les maladies tropicales négligées liées à la peau Ce programme a non seulement le potentiel de stimuler la recherche clinique, mais d'ouvrir la voie à de nouvelles interventions qui peuvent avoir un impact significatif sur la vie des individus.
Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Long-Term Extension Trial of a Novel Therapeutic Aryl Hydrocarbon Receptor Modulating Agent
Main Article Content Bruce Strober Yale University, New Haven & Central Connecticut Dermatology Research, Cromwell, CT, USA, Linda Stein Gold Henry Ford Health System, Detroit, MI, USA Robert Bissonnette Innovaderm Research Inc., Montreal, QC, Canada April Armstrong Keck School of Medicine at University of Southern California, Los Angeles, CA, USA Andrew Blauvelt Oregon Medical Research Center, Portland, OR, USA Philip Brown Dermavant Sciences, Inc., Morrisville, NC, USA Leon Kircik Mount...
Effects of Ruxolitinib Cream in Patients With Atopic Dermatitis With Head and/or Neck Involvement
Main Article Content Eric Simpson Oregon Health & Science University, Portland, OR, USA Robert Bissonnette Innovaderm Research, Montreal, QC, Canada Michael Kuligowski Incyte Corporation, Wilmington, DE, USA May Venturanza Incyte Corporation, Wilmington, DE, USA Kang Sun Incyte Corporation, Wilmington, DE, USA Jonathan Silverberg George Washington University School of Medicine Keywords ruxolitinib cream, atopic dermatitis, head and/or neck Abstract N/A References 1. Langan SM, et al. Lancet.
Tapinarof Cream 1% Once Daily for the Treatment of Moderate to Severe Atopic Dermatitis in Children and Adults: The Pivotal Phase 3 ADORING Clinical Program | SKIN The Journal of Cutaneous Medicine
Main Article Content Lawrence Eichenfeld UC San Diego Jonathan Silverberg George Washington University School of Medicine Robert Bissonnette Innovaderm Research Inc., Montreal, QC, Canada Anna Tallman Dermavant Sciences, Inc., Morrisville, NC, USA David Rubenstein Dermavant Sciences, Inc., Morrisville, NC, USA Stephen Piscitelli Dermavant Sciences, Inc., Morrisville, NC, USA John Jett Dermavant Sciences, Inc., Morrisville, NC, USA Keywords tapinarof, atopic dermatitis, ADORING trial Abstract...
The preponderance of evidence supports an AhR-dependent mechanism of action of tapinarof
Article Info Publication History Accepted: March 1, 2021 Received: February 26, 2021 Publication stage In Press Journal Pre-Proof Footnotes Original Article: Tapinarof in the treatment of psoriasis: A review of the unique mechanism of action of a novel therapeutic AhR modulating agent (TAMA) Commentary Article: The mode of action of tapinarof may not solely depend on the activation of cutaneous AHR signaling but also on its antimicrobial activity. Thomas Haarmann-Stemmann, PhD, Thomas R.
Biomarkers in atopic dermatitis-a review on behalf of the International Eczema Council
Atopic dermatitis (AD) is a common yet complex skin disease, posing a therapeutic challenge with increasingly recognized different phenotypes among variable patient populations. Because therapeutic response may vary on the basis of heterogeneous clinical and molecular phenotypes, a shift toward precision medicine approaches may improve AD management.
Tapinarof in the treatment of psoriasis: A review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor-modulating agent
Tapinarof, a novel, first-in-class, small-molecule topical therapeutic aryl hydrocarbon receptor (AhR)–modulating agent, is in clinical development for the treatment of psoriasis and atopic dermatitis.
Efficacy of Tapinarof Cream by Body Region in Subjects With Plaque Psoriasis in a Phase 2b Randomized Controlled Study
This work is licensed under a Creative Commons Attribution 4.0 International License. Authors transfer copyright to the publisher as part of the journal publishing agreement. All reprints are subject to the reprint policy.
The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis
Background An Investigator Global Assessment (IGA) is recommended by health agencies for drug registration in atopic dermatitis (AD). Current IGA scales lack standardization. Objectives To develop an IGA scale, training module, and clinical certification examination for use in AD trials; establish content validity; and assess reliability. Methods Expert dermatologists participated in the development of the validated IGA for AD (vIGA-ADTM).
Tape strips detect distinct immune and barrier profiles in atopic dermatitis and psoriasis
Background Our current understanding of atopic dermatitis (AD) and psoriasis pathophysiology is largely derived from skin biopsy studies that cause scarring and may be impractical in large-scale clinical trials. Although tape strips show promise as a minimally invasive technique in these common diseases, a comprehensive molecular profiling characterizing and differentiating the 2 diseases in tape strips is unavailable.
Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis: A Phase 2 Randomized Clinical Trial
Key Points Question Does the oral Janus kinase 1 selective inhibitor abrocitinib improve atopic dermatitis signs and symptoms in adults with moderate to severe atopic dermatitis at doses that are well tolerated? Findings In this randomized, double-blinded, phase 2b clinical trial including 267 participants, the proportion of patients achieving substantial improvement from baseline was significantly greater for those receiving 200 mg and 100 mg of abrocitinib compared with placebo.
Crisaborole and atopic dermatitis skin biomarkers: An intrapatient randomized trial
Atopic dermatitis (AD) has a high prevalence, approaching 25% in children and 10% in adults, depending on country of residence.1x1Brunner, P.M., Guttman-Yassky, E., and Leung, D.Y. The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies. J Allergy Clin Immunol. 2017; 139: S65–S76 Abstract | Full Text | Full Text PDF | PubMed | Scopus (100) | Google ScholarSee all References, 2x2Brunner, P.M., Leung, D.Y.M., and Guttman-Yassky, E.
Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis
Atopic dermatitis (AD) is a common inflammatory skin disease of increasing prevalence that affects 3% to 10% of adults and 10% to 20% of children globally.1x1Malajian, D. and Guttman-Yassky, E. New pathogenic and therapeutic paradigms in atopic dermatitis. Cytokine. 2014; 73: 311–318 Google ScholarSee all References, 2x2Guttman-Yassky, E., Dhingra, N., and Leung, D.Y. New era of biological therapeutics in atopic dermatitis. Expert Opin Biol Ther.
PLOS ONE: Correction: Based on Molecular Profiling of Gene Expression, Palmoplantar Pustulosis and Palmoplantar Pustular Psoriasis Are Highly Related Diseases that Appear to Be Distinct from Psoriasis Vulgaris
During submission, an incorrect Fig 5 showing heat map results instead of immunohistochemistry results was erroneously inserted. Please view the correct Fig 5 here. Representative images of ADAM23 and GPRIN1 localization in normal acral skin, psoriasis vulgaris and PPPP as shown by immunohistochemistry. There is an increase in expression of ADAM23 and GPRIN1 in PPPP as compared to psoriasis vulgaris and normal acral skin.
PLOS ONE: Based on Molecular Profiling of Gene Expression, Palmoplantar Pustulosis and Palmoplantar Pustular Psoriasis Are Highly Related Diseases that Appear to Be Distinct from Psoriasis Vulgaris
There is a controversy surrounding the existence of palmoplantar pustulosis (PPP) and palmoplantar pustular psoriasis (PPPP) as separate clinical entities or as variants of the same clinical entity. We used gene expression microarray to compare gene expression in PPP and PPPP. Skin biopsies from subjects with PPP (3), PPPP (6), psoriasis vulgaris (10) and acral skin from normal subjects (7) were analyzed using gene expression microarray.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Robert
Contact Robert, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack